Scienture Holdings (SCNX) Announces Cancelation of ELOC

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced it has terminated its Equity Line of Credit (“ELOC”) facility effective as of May 22, 2025.

In connection with cancellation of the ELOC, on June 16, 2025, the Company filed a post-effective amendment to the Registration Statement on Form S-1 (File No. 333-283591) filed with the Securities and Exchange Commission on December 3, 2025, declared effective on February 14, 2025. The post-effective amendment deregisters all 310,488 unsold shares of the Company’s common stock that had been registered under the registration statement.

This strategic financial decision comes as the Company prepares to commercially launch its first FDA-approved product candidate, Arbli™, which is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market.

"This move allows management to focus more on our planned commercialization of Arbli™ upcoming in summer 2025,” said Shankar Hariharan, Co-Chief Executive Officer and Executive Chairman. “We believe that it is in the Company’s best interest to cancel the ELOC facility as we prepare for the commercial launch of Arbli™ and seek more favorable financing terms to support the Company’s near and long-term growth strategy.”

"We are at a critical moment in our Company’s history as we quickly approach our target date for commercially lauunching Arbli™ this summer,” commented Naraismhan Mani, Co-Chief Executive Officer and President. “Cancelling the ELOC facility represents a commitment by our management to focus on the commercial launch and finding more favorable funding opportunities to support our strategic plans.”

The Company continues to expect that it will commercially launch Arbli™ by making it available to patients in the U.S. during Q3 2025. Arbli™ is indicated for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy, and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes.

You May Also Be Interested In

• Lumen Technologies to move stock listing from NYSE to Nasdaq
• CDT Equity announces 1-for-25 reverse stock split on Nasdaq
• Strive Enterprises (ASST) Reiterated at Buy by StoneX on Launch of Digital Credit ETF